The complaint, filed in the U.S. District Court for the District of New Jersey under the title Apitz-Grossman v. Embecta Corp., asserts violations of the Securities Exchange Act of 1934. According to the filing, Embecta leadership previously described its insulin pen line as showing a "slight positive trend" and "resilience," even as the company faced mounting market softness and increased competition.

This discrepancy became apparent when the medical device manufacturer released its second-quarter results. The company admitted to significant share loss within its pen needle category and a downturn in retail volume. The market reaction was swift, driving the stock price from $9.25 to $3.90 per share in a single session. Alongside the revenue miss, Embecta slashed its quarterly dividend from $0.15 to $0.01 per share. Investors seeking to participate as lead plaintiffs in the litigation must petition the court by August 17, 2026.